A Clinical Study of the Efficacy and Safety of Shenyankangfu Tablets in the Treatment of Primary Glomerulonephritis and Diabetic Kidney Disease

A Clinical Study of the Efficacy and Safety of Shenyankangfu Tablets in the Treatment of Primary Glomerulonephritis and Diabetic Kidney Disease?????????????????????????????????

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003612

Enrollment

Unknown

Registered

2013-09-13

Start date

2013-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Glomerulonephritis and Diabetic Kidney Disease

Interventions

1:shenyankangfu tablets + Losartan potassium tablets mimetic agent×2

2:shenyankangfu tablets mimetic agent +losartan potassium tablets 50mg +losartan potassium tablets mimetic agent

3:shenyankangfu tablets mimetic agent +losartan potassium tablets 50mg×2

4:shenyankangfu tablets + Losartan potassium tablets 50mg+ losartan potassium tablets mimetic agent

5:shenyankangfu tablets +losartan potassium tablets 50mg×2

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary glomerulonephritis or diabetic kidney disease and included in the period of CKD1 ~ 3A; 2. Aged from 18 to 70 yearsmale or female; 3. Blood pressure can be controlled under 140/90mmHg; 4. GFR >=45ml/min/1.73?; 5. 0.5g<=24 h proteinuria<=3.0g; 6. HbA1c of patient with Diabetic Kidney Disease <=8%; 7. Traditional Chinese medicine syndrome conform Qi-Yin Deficiency; 8. Obtain the agreement of patients or their guardians, and signed informed consent file.

Exclusion criteria

Exclusion criteria: 1. Henoch-Schonlein purpura nephritis, lupus nephritis, systemic small vasculitis kidney damage, gouty nephropathy, Myeloma nephropathy and other secondary nephropathy; 2. Take the glucocorticoid, immunosuppressants and triptolide medications in the last 3 months; 3. Take other Chinese patent medicine and decoction whicn can reduce proteinuria in the last 2 weeks; 4. Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient’s life; 5. Pregnant or lactating women; 6. Allergic predisposition or known to be allergic to the drug composition; 7. Blood presser <90/60mmHg; 8. Patient with unilateral or bilateral renal artery stenosis; 9. Patients with mental disorders and poor compliance; 10. Patiens are suspected or confirmed with alcohol, drug abuse history; 11. Patines who is participating in another clinical study at the same period.

Design outcomes

Primary

Measure	Time frame
24 hours Proteinuria;White blood cells;	—

Secondary

Measure	Time frame
Serum creatinine;eGFR;symptom scores;serum albumi;	—

Countries

China

Contacts

Public ContactXiangmei Chen

Chinese PLA General Hospital

xmchen301@126.com+86 010 66935462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026